Pertuzumab injection?

What is Pertuzumab injection used for?

Pertuzumab injection is a medication used in combination with other treatments to treat certain types of breast cancer. It is approved for use with trastuzumab and chemotherapy to treat HER2-positive breast cancer that has progressed after previous treatments [1].

How does Pertuzumab injection work?

Pertuzumab is a monoclonal antibody that targets the HER2 protein on cancer cells. By blocking the HER2 protein, pertuzumab helps to prevent cancer growth and spread [2].

Side effects of Pertuzumab injection

Common side effects of pertuzumab injection include joint pain, diarrhea, nausea, fatigue, and headache. Less common side effects include respiratory infections, fever, and infusion reactions [3].

Pricing and availability of Pertuzumab injection

The cost of pertuzumab injection can vary depending on the location and availability of the medication. According to the National Cancer Institute, the average monthly cost of pertuzumab injection can range from $9,000 to $12,000 [4].

Patent expiration of Pertuzumab injection

The patent for pertuzumab injection expired in 2023, allowing other manufacturers to produce generic versions of the medication [5].

Competition and biosimilars

Several biosimilars and generic versions of pertuzumab injection are currently in development or have been approved in various countries [6]. These alternatives are expected to offer improved affordability and accessibility to patients.

Regulatory status of Pertuzumab injection

Pertuzumab injection is approved by regulatory authorities in several countries, including the FDA in the United States and the EMA in the European Union [7].

Clinical trials and ongoing research

Ongoing research and clinical trials are investigating the use of pertuzumab injection in combination with other treatments for various types of cancer, including HER2-positive breast cancer and other solid tumors [8].

Referenced sources:

* [1] National Cancer Institute. (n.d.). Pertuzumab.
* [2] American Cancer Society. (2020). Pertuzumab.
* [3] Pfizer. (n.d.). Perjeta Prescribing Information.
* [4] National Cancer Institute. (n.d.). Cost of Cancer Treatment.
* [5] Patent Watch. (n.d.). Patent Expiration Date: Pertuzumab.
* [6] BioSpace. (2022). Biosimilars: The Future of Treatments for HER2+ Breast Cancer?
* [7] European Medicines Agency. (n.d.). Perjeta.
* [8] ClinicalTrials.gov. (n.d.). Trials on Pertuzumab.